Serum thrombopoietin level after allogeneic bone marrow transplantation: Possible correlations with platelet recovery, acute graft-versus-host disease and hepatic veno-occlusive disease

International Journal of Hematology

Volumn 64, Issue 3-4, 1996, Pages 241-248

  Hamaguchi, Motohiro ^a   Yamada, Hironori ^b   Morishima, Yasuo ^c,f   Morishita, Yoshihisa ^d   Kato, Yukio ^d   Sao, Hiroshi ^c   Kanie, Tadaharu ^a   Murata, Makoto ^a   Taji, Hirofumi ^a   Nakayama, Yukiko ^a   Minami, Saburo ^a   Saito, Hidehiko ^e   Kodera, Yoshihisa ^a  

^a JAPANESE RED CROSS NAGOYA FIRST HOSPITAL   (Japan)

^b Nagoya Ekisaikai Hospital   (Japan)

^c Meitetsu Hospital   (Japan)

^d Showa Hospital   (Japan)

^e NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f AICHI CANCER CENTER HOSPITAL   (Japan)

Author keywords

Allogeneic BMT; GVHD; Thrombopoietin; VOD

Indexed keywords

THROMBOPOIETIN;

ADOLESCENT; ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; LIVER; MALE; PRIORITY JOURNAL; THROMBOCYTE COUNT; VEIN OCCLUSION;

EID: 0030273169     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1016/0925-5710(96)00487-2     Document Type: Article

References (27)

1. [1] de Sauvage FJ, Mass PE, Spencer SD et al. Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mp1 ligand. Nature 1994;369:533-538.
2. [2] Lok S, Kaushansky K, Holly RD et al. Cloning and expression of murine thrombopoietin cDNA and stimulation of platelet production in vivo. Nature 1994;369:565-568.
3. [3] Kaushansky K, Lok S, Holly RD et al. Promotion of megakaryocyte progenitor expansion and differentiation by the c-Mp1 ligand thrombopoietin. Nature 1994;369:568-571.
4. [4] Wendling F, Maraskovsky E, Debili N et al. c-Mp1 ligand is a humoral regulator of megakaryocytopoiesis. Nature 1994;369:571-574.
5. [5] Bartley TD, Bogenberger J, Hunt P et al. Identification and cloning of a megakaryocyte growth and development factor that is a ligand for the cytokine receptor Mp1. Cell 1994;77:1117-1124.
6. [6] Kato T, Ogami K, Shimada Y et al. Purification and characterization of thrombopoietin. J Biochem 1995;118:229-236.
7. [7] Kaushansky K. Thrombopoietin: the primary regulator of platelet production. Blood 1995;86:419-431.
8. [8] Kaushansky K. Thrombopoietin: basic biology, clinical promise. Int J Hematol 1995;62:7-15.
9. [9] Nichol JL, Hokom MM, Hornkohl A et al. Megakaryocyte growth and development factor. Analyses of in vitro effects on huma megakaryopoiesis and endogenous serum levels during chemotherapy-induced thrombocytopenia. J Clin Invest 1995;95:2973-2978.
10. [10] Kuter DJ, Rosenberg RD. The reciprocal relationship of thrombopoietin (c-Mp1 ligand) to changes in the platelet mass during busulfan-induced thrombocytopenia in the rabbit. Blood 1995;85:2720-2730.
11. [11] Meng YG, Martin TG, Peterson ML, Shuman MA, Cohen RL, Wong WL. TPO regulation following bone marrow transplantation. Blood 1995;86(Suppl):313a (abstract).
12. [12] First LR, Smith BR, Lipton J, Nathan DG, Parkman R, Rappeport JM. Isolated thrombocytopenia after allogeneic bone marrow transplantation: existence of transient and chronic thrombocytopenic syndromes. Blood 1985;65:368-374.
13. [13] Anasetti C, Rybka W, Sullivan KM, Banaji M, Slichter SJ. Graft-v-host disease is associated with autoimmunelike thrombocytopenia. Blood 1989;73:1054-1058.
14. [14] Rio B, Andrew G, Nicod A et al. Thrombocytopenia in veno occlusive disease after bone marrow transplantation or chemotherapy. Blood 1986;67:1773-1776.
15. [15] Tahara T, Usuki K, Sato H et al. Serum thrombopoietin levels in healthy volunteers and patients with various disorders measured by enzyme immunoassay. Blood 1994;84(Suppl):910a (abstract).
16. [16] Sohma Y, Akahori H, Seki N et al. Molecular cloning and chromosomal localization of the human thrombopoietin gene. FEBS Lett 1994;353:57-61.
17. [17] Kuter DJ, Beeler DL, Rosenberg RD. The purification of megapoietin: a physiological regulator of megakaryocyte growth and platelet production. Proc Natl Acad Sci USA 1994;91:11104-11108.
18. [18] Thomas ED, Storb R, Clift RA et al. Bone-marrow-transplantation. N Engl J Med 1975;292:832-884.
19. [19] Martin PJ, Schoch G, Fisher L et al. A retrospective analysis of therapy for acute graft-versus-host disease: initial treatment. Blood 1990;76:1464-1472.
20. [20] Marks DJ, Doussert B, Robson A et al. Orthotopic liver transplantation for hepatic GVHD following allogeneic BMT for chronic myeloid leukaemia. Bone Marrow Transplant 1992;10:463-466.
21. [21] Bligh J, Morton J, Durrant S, Walker N. Oncocytic metaplasia of bile duct epithelium in hepatic GVHD. Bone Marrow Transplant 1995;16:317-319.
22. [22] Rapoport AP, Doyle HR, Starzl T, Rowe JM, Doeblin T, DiPersio JF. Orthotopic liver transplantation for life-threatening veno occlusive disease of the liver after allogeneic bone marrow transplant. Bone Marrow Transplant 1991;8:421-424.
23. [23] Espigado I, Rodriguez JM, Parody R, Carmona M, Digon J, Olloqui E. Reversal of severe hepatic veno-occlusive disease by combined plasma exchange and rt-PA treatment. Bone Marrow Transplant 1995;16:313-316.
24. [24] Schlitt HJ, Tischler HJ, Ringe B et al. Allogeneic liver transplantation for hepatic veno-occlusive disease after bone marrow transplantation - clinical and immunological considerations. Bone Marrow Transplant 1995;16:473-478.
25. [25] Shulman HM, McDonald GB, Matthews D et al. An analysis of hepatic degeneration following bone marrow transplantation. Bone Marrow Transplant 1992;10:197-214.
26. [26] Shivdasani RA, Rosenblatt MF, Zucker-Franklin D et al. Transcription factor NF-E2 is required for platelet formation independent of the actions of thrombopoietin/ MGDF in megakaryocyte development. Cell 1995;81:695-704.
27. [27] Emmons RVB, Shulman NR, Reid DM et al. Thrombocytopenic patients with aplastic anemia have high TPO levels whereas those with immune thrombocytopenia are much lower. Blood 1995;86:372a.